Curis (CRIS) to Release Earnings on Thursday

Curis (NASDAQ:CRIS) will issue its quarterly earnings data before the market opens on Thursday, November 1st. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.15. Curis had a negative net margin of 407.29% and a negative return on equity of 225.77%. The company had revenue of $2.36 million for the quarter, compared to the consensus estimate of $2.41 million. On average, analysts expect Curis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:CRIS opened at $1.54 on Wednesday. Curis has a twelve month low of $1.36 and a twelve month high of $8.15. The company has a current ratio of 3.01, a quick ratio of 3.01 and a debt-to-equity ratio of 4.43.

CRIS has been the topic of several research reports. Cowen reiterated a “buy” rating on shares of Curis in a report on Monday, August 6th. Zacks Investment Research upgraded shares of Curis from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Wednesday, August 8th. Finally, SunTrust Banks cut their price target on shares of Curis to $8.00 and set a “buy” rating on the stock in a report on Friday, August 3rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Curis presently has an average rating of “Buy” and an average price target of $13.33.

About Curis

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Recommended Story: Asset Allocation and Your Retirement

Earnings History for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with's FREE daily email newsletter.

Leave a Reply